Osmotica Pharmaceuticals Plc (OSMT)

4.12
NASDAQ : Health Technology
Prev Close 4.13
Day Low/High 4.05 / 4.24
52 Wk Low/High 2.20 / 9.90
Avg Volume 86.80K
Exchange NASDAQ
Shares Outstanding 52.52M
Market Cap 216.90M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Vertical Pharmaceuticals, LLC, An Osmotica Company, Announces Submission Of New Drug Application For RVL-1201

Vertical Pharmaceuticals, LLC, An Osmotica Company, Announces Submission Of New Drug Application For RVL-1201

--RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) is a potential first-in-class pharmacologic treatment option for acquired blepharoptosis (droopy eyelid)--

Osmotica Pharmaceuticals Plc Reports Second Quarter 2019 Results

Osmotica Pharmaceuticals Plc Reports Second Quarter 2019 Results

Second quarter 2019 total revenue of $57.5 million On track to submit NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.

Shareholder Rights Law Firm Johnson Fistel Launches Investigations

Shareholder Rights Law Firm Johnson Fistel Launches Investigations

SAN DIEGO, July 2, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims for violations of federal law against the following companies that recently issued stock in connection with an initial public...

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Osmotica Pharmaceuticals Plc Investors

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Osmotica Pharmaceuticals Plc Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Osmotica Pharmaceuticals plc investors ("Osmotica" or the "Company") (NASDAQ:  OSMT) concerning the Company and its officers' possible violations of federal securities laws.

SHAREHOLDER ALERT: Investigation Of Osmotica Announced By Holzer & Holzer, LLC

SHAREHOLDER ALERT: Investigation Of Osmotica Announced By Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether certain statements made by Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ: OSMT) complied with federal securities laws.